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Abstract
Increasing evidence shows that the cells associated with atherogenesis (platelets, endothelial
and smooth muscle cells, fibroblasts, monocytes, macrophages and T lymphocytes) express pro-
inflammatory pathways of CD40 signalling. Activation of platelets CD40/CD40L system and
its counterpart CD40 receptors on vascular cell surface induces the expression of various
adhesion molecules, cytokines, chemokines, growth factors, matrix metalloproteinases and
reactive oxygen species, the substances which are responsible for plaque formation,
destabilisation and rupture. Disturbed laminar blood flow (low wall shear stress) can mediate
CD40/CD40L system signalling by increasing the residence time of the interaction between
platelets and endothelium.
Experimental studies provide considerable data indicating that interruption of CD40 signal-
ling significantly inhibits the progression of established atheroma and altered plaque composi-
tion for a lipid-poor collagen-rich stable plaque phenotype. Recent data suggest different aspects
of CD40/CD40L system activation in the context of risk factors (hypercholesterolaemia, diabe-
tes mellitus, obesity and cigarette smoking) link them into the pro-inflammatory and pro-
thrombotic milieu, aggravating the atherosclerotic process. Activation of the CD40/CD40L
system plays a pivotal role in acute coronary syndromes as well as acute cerebral ischaemia.
After percutaneous coronary intervention the risk of restenosis increases with high levels of
plasma-soluble CD40L (sCD40L). In apparently healthy women sCD40L concentration has
been recognised as an independent risk factor of the first acute coronary event. Clopidogrel,
aspirin, statins and some oral hypoglycaemic agents share common anti-inflammatory proper-
ties including inhibition of CD40/CD40L intercellular signalling. To prevent plaque progres-
sion, destabilisation and thrombotic complications, anti-platelet treatment strategy should be
focused on inhibition of platelet activation instead of on response to platelet aggregation. (Folia
Cardiol. 2006; 13: 283–292)
CD40/CD40L system, platelets, atherosclerosis
Pro-inflammatory activities
of the CD40/CD40L system
Platelets are involved not only in homeostasis
and thrombosis, but also, as is increasingly recogni-
sed, in atherosclerotic lesion formation and reste-
nosis processes. “Some data indicate that at sites
predisposed for atherosclerotic development like
artery bifurcations, T-junctions, turbulent flow can
induce endothelial overexpression of adhesion
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molecules” [1]. Numerous observations provide
evidence that the pro-inflammatory CD40/CD40L
system may be involved in this process.
There are continuous mechanical and humoral
responses to the endothelium and blood flow [2].
Disturbed laminar blood flow (turbulent, pulsatile
or reverse flow) can lead not only to endothelial cell
dysfunction but also to structural modifications of
cells. In low wall shear stress endothelial cells be-
come more rounded and display a polygonal non-
oriented shape. Because of high cell turnover, intra-
cellular junctions become leaky, allowing an incre-
ase in the influx of macromolecules, platelet adhesion
and leukocyte recruitment [2–6]. In contrast, the
steady unidirectional laminar high blood-flow pro-
tects against atherosclerotic plaque formation [7, 8].
It has become increasingly clear that locally
disturbed laminar flow is at the root of atheroscle-
rosis and its complications. Atherosclerotic plaqu-
es are not distributed at random but there is a cha-
racteristic topographic distribution pattern. Athe-
rosclerotic lesions tend to be found almost
exclusively at specific arterial sites such as the pro-
ximal segments of coronary and renal arteries,
major bifurcations and T-junctions [3, 9–11]. The
progression of atheromatosus plaque is usually ec-
centric and the location well-defined. Sabbah at al.
[13, 14] documented that the inner walls of the co-
ronary arteries are particularly prone to artherosc-
lerotic plaque formation. In the thoracic aorta the
highest prevalence of fatty streaks occurred in the
dorsal surface with the highest prevalence midway
between successive pairs of intercostal ostia [11].
In spite of the fact that traditional risk factors
are systemic (such as hypercholesterolaemia, dia-
betes mellitus, tachycardia, hypertension, cigaret-
te smoking and obesity) the distribution of athero-
matosus plaques is restricted to the specific sites
mentioned above only in large and medium-size
arteries in which, according to Reynolds’ equation,
there are suitable conditions for disturbed laminar
blood flow. This means that in atherosclerotic de-
velopment certain hemodynamic features like blo-
od velocity and flow pattern should be considered
[15, 16]. There is a positive association between the
distribution of atheromatosus plaques and low wall
shear stress, a finding that does not run contrary to
the observation that accelerated flow through ste-
nosis can promote platelet activation [17–21]. One
can speculate that the initiation and evolution of
atheroma is related to low shear rate, the hemody-
namic factor that increases the residence time of
interaction between platelets and endothelium. This
can predispose to pro-inflammatory communication
between the CD40/CD40L system and the endothe-
lial cells, especially when plasma viscosity is high,
as has been shown to be the case in patients with
typical cardiovascular risk factors.
In arteries with a defective endothelium a pa-
radoxical reaction is observed. At sites of early athe-
rosclerosis acetylcholine rather than vasodilatation
provokes vasoconstriction and predisposes to di-
sturbance of laminar flow [22]. Under conditions of
disturbed flow platelets and endothelial cells rele-
ase adhesion molecules, chemokines, cytokines and
growth factors active in pro-inflammatory and pro-
coagulant responses. This increases the adhesive-
ness of the endothelium with respect to platelets
as well as other morphological blood elements, ag-
gravating the chronic inflammatory reaction of pla-
que formation [23]. Because of its broad biological
activity, the CD40/CD40L system has emerged as
one of the most important players in the atherosc-
lerotic process.
Despite the fact that platelets are anucleate
blood cells, they posses high proinflammatory pro-
perties and, upon activation, are able to release
chemokines and synthesise some cytokines (inter-
leukin-1b) [24]. The CD40 ligand (CD40L, CD154)
is a transmembrane protein (39 kDa), structurally
related to the cytokine TNF-a. CD40 is a 50 kDa
integral membrane protein of the TNF receptor fa-
mily. The CD40/CD40L system is expressed on
a variety of immunological and vascular cells that
are major players in atherosclerosis, namely acti-
vated T lymphocytes, monocytes, macrophages and
endothelial and smooth muscle cells, but platelets
are the major contributor of the soluble CD40 form
(sCD40L, 18 kDa). It is estimated that 95% of the
circulating sCD40L is derived from platelets [25–
–27] (Table 1). It is calculated that 108 platelets con-
tain about 2.5 ng CD40L but the possibility cannot
be excluded that some circulating sCD40L can be
Table 1. Immunological and vascular cells
expressing CD40/CD40L system (adapted
according to [34])
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derived from endothelial cells, monocytes and ac-
tivated T lymphocytes [27–36].
CD40L is not stored in a-granule but in plate-
let cytosol. Normally absent on the surface of unsti-
mulated platelets, CD40L is present within seconds
on the platelet surface and rapidly cleaves to gene-
rate a biologically active soluble fragment (sCD40)
[26, 31]. Like platelet-selectin (sP-selectin) and
platelet-monocyte aggregates, soluble CD40L is
regarded as a sensitive marker of in vivo platelet
activation [35–37].
The low wall shear stress promotes binding of
the CD40 ligand presented on activated platelets,
T lymphocytes and monocytes to the CD40 recep-
tors expressed on vascular cells. As a consequence
of CD40 ligation to its receptor, several pro-athe-
rogenic processes are initiated [38].CD40L binding
enhances synthesis of adhesion molecules [39].
Activated platelets aggregate with leukocytes and
more easily adhere to endothelium [40, 41]. The
cells associated with atherosclerotic lesion exhibit
abundant expression of CD40 on their surface.
CD40/CD40L signalling is a crucial mediator not
only in the initial events of atherogenesis but also
in the progression and thrombotic complications of
atheroma. Ligation of CD40L expressed on plate-
lets and immunological cells to the endothelium,
smooth muscle cells and fibroblasts not only results
in abundant expression of adhesion molecules (se-
lectin, VCAM-1, ICAM-1) [26, 42–46] on those cells
but also stimulates chemokine production (IL-8,
RANTES MCP-1, MIP-1a) [47–51]. In vitro CD40/
/CD40L activation in endothelial and smooth mu-
scle cells and monocytes increases the generation
of atherogenic cytokines (IL-1, IL-6, IL-12, IFN-g,
TNFa) and growth factors (Table 2) [38, 52]. Key
elements of atherosclerotic lesions, adhesion mo-
lecules, are expressed mainly in areas of low wall
shear stress, promoting the recruitment of plate-
lets, monocytes and lymphocytes to dysfunctional
endothelium.
The importance of adhesion molecules in athe-
rogenesis has been demonstrated in experimental
models. In apolipoprotein E-deficient mice (ApoE-/-)
inhibition of different adhesion molecules attenu-
ates or protects against atherosclerosis [53–55]. In
mouse models engineered for accelerated athero-
sclerosis administration of the CD40L blocking an-
tibody or targeting of the CD40L gene greatly inhi-
bits the initiation of lesions and makes the plaque
phenotype more stable. The lesions of anti-CD40L-
-treated mice exhibit more smooth muscle cells and
interstitial collagen and have reduced lipid-content,
fewer macrophages and T lymphocyte. Disruption of
CD40/CD40L signalling is associated with downregu-
lation of the expression of adhesion molecules such
as VCAM-1 and matrix metalloproteinases [56–58].
The long-term blockade of CD40/CD40L sup-
press murine cardiac allograft arteriopathy, impro-
ve graft function and decrease allograft endothelial




sCD40L is a bifunctional protein, being invo-
lved in both thrombosis and inflammation. CD40/
/CD40L interaction promotes thrombotic activity by
means of matrix metalloproteinase-enhanced func-
tion. This leads to more a fragile plaque phenoty-
pe, prone to rupture and thrombus formation. Acti-
vation of CD40/CD40L increases tissue factor
expression on macrophages and endothelial cells
and this is the second reason why the CD40/CD40L
system is engaged in procoagulant activity [60, 61].
The thrombotic sCD40 ligand properties are also
due to a KGD sequence located near the amino
Table 2. Pro-inflammatory molecules stimulated by CD40/CD40L signalling in atheroma-associated
cells (adapted according to [34])
Cytokines: IL-1a/b, IL-2, IL-5, IL-8, IL-10, IL-12, IL-15, IL-18, TNF-a/b, INF-g
Adhesion molecules: P-selektin, E-selektin, ICAM-1, VCAM-1
Growth factors: VEGF, FGF, M-CSF, GM-CSF
Chemokines: IL-8, MCP-1, RANTES, MIP-1a/b
Metalloproteinases: MMP from 1 to 13
Procoagulant: TF
IL — interleukin, TNF — tumour necrosis factor, INF — interferon, ICAM — intercellular adhesion molecule, VCAM — vascular cell adhesion molecule,
VEGF — vascular endothelial growth factor, FGF — fibroblast growth factor, M-CSF — monocyte colony stimulating factor, GM-CSF — granulocyte/
/monocyte colony stimulating factor, MCP — monocyte chemotactic protein, RANTES — regulated on activation normal T cell expressed and secre-
ted, MIP — macrophage inflammatory protein, MMP — matrix metalloproteinases, TF — tissue factor
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terminus that allows the protein to bind to aIIbb3 re-
ceptors, promoting stable platelet aggregate forma-
tion [62]. The absence of CD40L affects the stabili-
ty of arterial thrombi and delays arterial occlusion
in vivo. Infusion of recombinant soluble CD40L re-
stores normal thrombosis [62].
Activation of endothelial cell CD40 receptors
enhances reactive oxygen species production and
inhibits endothelial cell migration. The reactions
may play a crucial role when vessel injury occurs
(plaque erosion or PTCA). Because the activation
of CD40 receptors inhibits re-endotheliasation, the
risks of thrombus formation or the restenosis pro-
cess are increased [63].
CD40/CD40L as a marker
of inflammation
The risk factors of atherosclerosis are featu-
res which are more frequently present in patients
who are ill in comparison to healthy persons. The
correlation between atherosclerosis and risk factors
is, in fact, not causal but strictly statistical. Hyper-
tension, hypercholesterolaemia or cigarette smo-
king double the risk of coronary artery disease. The
risk in diabetic patients is even higher, but hyper-
tension and hypercholesterolaemia concomitant
with diabetes multiply the risk. It can safely be spe-
culated that the risk factors promote the atherosc-
lerotic process through a common pathological
mechanism. Such an assumption can explain why
the global risk is not the sum of single risk factors
and indicates that they act synergically.
There is a considerable overlap in predicted
risk between those subjects who did and those who
did not develop acute coronary syndromes and well-
known risk factors can account for the occurrence
of acute episodes in the minority of them [64–65].
Atherosclerosis is a multi-factorial dynamic and
progressive disease and there is increasing eviden-
ce to show that various inflammatory markers and
agents (sedimentation rate, fibrinogen, CRP prote-
in, interleukin 6, amyloid and ICAM-1) are involved
in this process [66–71]. The CD40/CD40L system
has recently joined this extensive list. In a prospec-
tive nested case-control study of apparently heal-
thy middle-aged women, (Women’s Health Study)
an elevated plasma concentration of sCD40L at ba-
seline foretold a significantly increased risk of fu-
ture cardiac events [72].
Epidemiological data has consistently demon-
strated a statistical correlation between different
markers of inflammation and atherosclerotic com-
plications but it remains unknown whether this re-
presents a marker or consequence of cardiovascu-
lar disease. Elevated sCD40L concentration can be
rendered an “innocent bystander” or, because of its




The plasma levels of CRP and interleukin-6 in
patients with non-insulin-dependent diabetes mel-
litus correlate positively with glucose level and in-
sulin resistance [74, 75]. Plasma TNF, plasminogen
activator inhibitor-1 (PAI-1) levels and platelet ac-
tivation are increased in diabetic patients with
a concomitant high level of sCD40L [76–80]. Varo
at al. [80] revealed that type 2 and type 1 diabetic
patients had a significantly higher sCD40 concen-
tration. Furthermore, high sCD40L levels positively
correlate with interleukin-6, tissue factor and dia-
betes control (HbA1c) [81]. CD40/CD40L system
activation in diabetics is manifested not only in
a high level of sCD40L but also in overexpression
of CD40 ligand and CD40 receptors on the plate-
lets surface [81].
Patients with hypercholesterolaemia, in com-
mon with those with diabetes, exhibit overproduc-
tion of different cytokines, chemokines and adhe-
sion molecules and platelet activation is observed.
CD40 and P-selectin expression on platelets cor-
relate with LDL cholesterol concentration [82–85].
The sCD40L levels are higher in patients with low
HDL cholesterol and correlate with sICAM, apoli-
poprotein B and a prothrombotic state [86–90].
Schönbeck at al. [91] suggest that oxidised LDL can
provide an initial signal for overexpression of the
CD40 receptor/ligand dyad in atherosclerotic plaque.
The clinical data linking hypertension and in-
flammation are scarce. In one study patients with
essential hypertension showed a significant overe-
xpression of CD40 on platelets as well as increased
sCD40L levels compared with controls [92].
Presumably, CD40/CD40L system may com-
bine with other risk factors such as cigarette smo-
king [93] and obesity [94–95]. Tobacco use upre-
gulates the CD40 expression on monocytes and
CD40L on the surface of platelets and favours the
platelet-monocyte aggregation involved in the in-
flammatory and thrombotic process [96]. High le-
vels of sCD40L and concentrations of adhesion
molecules (sICAM-1, sVCAM-1, sE-selectin, sP-se-
lectin) have been demonstrated in obese children [95].
CD40/CD40L interaction promotes atheroscle-
rosis independently of its vascular localisation [97].
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Evidence of CD40/CD40L activation accompanies
thrombotic complications of atherosclerosis (unsta-
ble angina, myocardial infarction and acute cerebral
ischaemia) [61, 73, 80, 98] and is associated with
percutaneous coronary interventions [73, 99, 100]
as well as cardiopulmonary bypass [29]. In patients
with chronic heart failure, soluble CD40L concen-
tration correlates with clinical severity, neurohor-
monal dysregulation and left ventricular dysfunc-
tion [101]. The high concentration of sCD40L, IL-6
and MCP-1 in pulmonary arterial hypertension may
suggest the involvement of CD40/CD40L signalling
in chemokine-related pathogenic mechani-
sms [102].
CD40/CD40L system overexpression may be
involved in the pathogenic mechanism of atherosc-
lerosis in patients from high-risk groups such as
those with Crohn’s disease, ulcerative colitis and
Kawasaki disease [32, 103]. Enhanced CD40/
/CD40L signalling and elevated serum concentra-
tions of cytokines are found in patients with the
autoimmune diseases of systemic lupus erythema-
tosus and rheumatoid arthritis. This may be a pivo-
tal mechanism in the creation of a pro-inflammato-
ry micro-environment which promotes the develop-
ment of accelerated atherosclerotic vascular disease
in this group of patients, especially when well-
known risk factors are absent [104–109].
CD40/CD40L in acute
coronary syndromes
Platelets from patients with unstable angina are
characterised by markedly decreased intracellular
CD40L levels as well as a decreased release of
sCD40L on stimulation. This indicates that in acu-
te coronary syndromes platelets are the source of
high concentrations of soluble CD40L [73]. Enhan-
ced activation of the CD40/CD40L system during
thrombotic complications of atherosclerosis con-
firms not only elevation of sCD40L concentration
but also overexpression of the CD40 ligand and
CD40 receptors on platelets and the CD40 ligand
on the surfaces of monocytes [61, 98, 99]. Concen-
trations of sCD40L correlate with the formation of
aggregates of monocyte-platelets [110]. There is
a positive correlation between MMP-9, MMP-3, and
CD40L expression on platelets as well as sCD40L
levels [61]. Patients with myocardial infarction have
higher concentrations of soluble CD40L compared
with patients with unstable angina. This finding indi-
cates that the patients with myocardial infarction have
increased hydrolysis of surface CD40L, but overe-
xpression of CD40L on platelets in unstable angina
can be a marker of platelet activation and an incre-
ased risk of acute thrombotic complications [98].
The OPUS-TIMI 16 (Orbofiban in Patients with
Unstable coronary syndromes) [110] and CAPTURE
(Chimeric c7E3 AntiPlatelet Therapy in Unstable
angina REfractory to standard treatment) [111] stu-
dies confirm that the intensity of CD40/CD40L sys-
tem activation is a powerful clinical marker for the
identification of the high-risk group among patients
with unstable angina. Patients with elevated serum
levels of sCD40L have a significantly greater risk of
major adverse cardiovascular events, including acu-
te myocardial infarction, sudden death and recurrent
angina [112]. In patients with unstable angina who
are negative for troponin, elevation of soluble CD40L
identifies a subgroup that is more likely to benefit
from anti-platelet treatment with abciximab [110].
CD40/CD40L and restenosis after
coronary angioplasty
Clopidogrel pretreatment reduces platelet ac-
tivation and CD40/CD40L signalling after mecha-
nically induced plaque rupture by percutaneous
transluminal coronary angioplasty (PTCA) [73, 99,
113]. After coronary angioplasty the concentration
of inflammatory markers (IL-6, CRP and sCD40L)
is increased [114]. The overexpression of adhesion
molecules (VCAM-1, ICAM-1, E-selectin) on endo-
thelial and smooth muscle cells is observed and
a high concentration of monocyte chemoattractant
protein-1 (MPC-1) is an independent strong predic-
tor of late restenosis [115, 116]. Elevated sCD40L
at baseline is significantly correlated with adhesion
molecules and MCP-1 generation after angioplasty
[117]. A high preprocedural level of sCD40L is an
independent predictor of late lumen loss. In addi-
tion, increased concentrations of sCD40L after
a procedure are more manifest and prolonged in re-
stenotic patients [117]. In vitro sCD40L may activa-
te monocyte and endothelial cells to release MIP-1
and reactivate oxygen species generation and inhi-
bit endothelial cell migration, a process considered
critical for the re-endotheliasation of the injured
vessel. The sCD40L-dependent endothelium and
monocyte-mediated inflammatory reaction after
PTCA may be one of the most important mechani-
sms of enhancing the restenotic process [63, 117].
Therapeutic modalities that
downregulate the CD40/CD40L system
During past decades anti-platelet treatment
concentrated on the inhibition of platelet aggregation,
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but increasing evidence shows that an equal or even
more critical issue in anti-platelet therapy is inhi-
bition of platelet activation. Results from the CA-
PRIE (Clopidogrel vs Aspirin in Patients at Risk of
Ischemic Events) and CURE (Clopidogrel in Unsta-
ble Angina to Prevent Recurrent Events) trials in-
dicate that clopidogrel therapy results in downre-
gulation of CD40/CD40L interaction with a conco-
mitant anti-inflammatory and antithrombotic effect
[118, 119]. There are four groups of drugs: clopido-
grel, aspirin, statins and some oral hypoglycaemic
agents which have in the common the ability to inhi-
bit CD40/CD40L signalling [31, 79, 91, 120, 121].
Intravenous glycoprotein IIb/IIIa antagonists
inhibit hydrolysis of sCD40L from the surface of
activated platelets. However, this does not prevent
translocation of intraplatelet CD40L stores to the
platelet surface [63, 64]. In the CAPTURE study
patients with the highest level of sCD40L benefi-
ted more from abciximab therapy [110]. Because
they protect against acute thrombotic complica-
tions, intravenous glycoprotein GP IIb/IIIa blockers
remain an adjunctive therapy for percutaneous co-
ronary intervention or a rescue therapy when
thrombotic complications occur.
The inhibitory effect of glycoprotein IIb/IIIa
antagonists is dose-dependent and suboptimal pla-
telet aggregation inhibition unexpectedly potentia-
tes the release of sCD40L from platelets CD40L
[121, 122]. Glycoprotein IIb/IIIa blockers given in
a sufficient dose, however, inhibit platelet aggre-
gation but do not prevent the platelet stimulation
induced by platelet agonists [123].
Despite their promise as active potent inhibi-
tors of platelet aggregation, oral platelet glycopro-
tein IIb/IIIa inhibitors have failed to bring about
a reduction in ischaemic events. In view of the risk
of increased bleeding events, sub-optimal inhibition
of platelet aggregation was probably one of the re-
asons why this therapeutic group of drugs has been
disappointing. A 16% increase in myocardial infarc-
tion was observed with oral glycoprotein IIb/IIIa
blockade without concurrent aspirin, together with
a statistically significant increase in bleeding com-
plications [124, 125]. Platelet aggregation affected
by lack of platelet glycoprotein GPIIb/IIIa comple-
xes in patients with Glanzmann thrombasthenia
does not protect against the development of athe-
rosclerosis [126]. These observations have argued
persuasively that ongoing platelet activation plays
an integral role in the pathophysiology of atherosc-
lerosis and shifts the focus of anti-platelet therapy
from aggregation inhibition to prevention of plate-
let activation. In addition, relatively weak platelet
antagonists, such as aspirin and the thienopyridines,
have brought about a relative reduction of about
25% in cardiovascular-event risk when administe-
red as secondary prevention.
Surface expression of CD40L is stimulated by
a variety of platelet agonists including ADP, colla-
gen, thrombin and tromboxane A2 [31]. As a result
of the cytoplasmatic localisation of platelet CD40L,
platelet stimulation by weak agonists may trigger
CD40L-dependent pathology even in the absence
of platelet secretion [26, 38]. Clopidogrel, by bloc-
king platelet P2Y12 purineric receptors, inhibits
ADP-induced CD40L expression and aspirin colla-
gen-induced sCD40L release [121, 127, 128].
Blockade of P2Y12 receptors can diminish com-
munication between platelets and monocytes, which
leads to a reduction in circulating platelet-leukocy-
te aggregates, monocyte tissue factor generation
and CD40L, P-selectin and GP IIb/IIIa receptor
expression on the surface of platelets, with a sub-
sequent antithrombotic and anti-inflammatory effect
[63, 129]. Aspirin use (325 mg for 7 days) results in
a 50% decrease in the release of sCD40L from col-
lagen-induced platelet aggregates [121]. These ob-
servations provide new insight into the mechanism
of anti-platelet therapy strategy.
Inhibition of platelet activation by aspirin and
clopidogrel downregulate pro-inflammatory and
prothrombotic platelet communication with vascu-
lar cells and lymphocytes and protect against the
release of various mediators of CD40/CD40L sys-
tem signalling. More pronounced platelet activation
inhibition can explain the prevalence of the combi-
ned therapy of aspirin and ticlopidine rather than
that of aspirin and warfarin for the prevention of the
serious complication of stent thrombosis [130]. The
COMMIT/CCS-2 (CLOpidogrel and Metoprolol in
Myocardial Infarction Trial/Second Chinese Cardiac
Study) and CLARITY-TIMI 28 (Clopidogrel as
Adjunctive Reperfusion Therapy-Thrombolysis in
Myocardial Infarction) trials revealed that the ad-
dition of clopidogrel to aspirin and fibrinolytic the-
rapy for myocardial infarction is superior with re-
gard to the patency rate of the infarct-related arte-
ry and reduces ischaemic complications without any
increase in haemorrhagic complications [131,132].
Lipid-lowering therapy downregulates CD40L
expression in atherosclerotic plaque [133] and even
after short periods of therapy statins diminish
CD40/CD40L signalling in monocytes, endothelial
and smooth muscle cells and lower plasma MCP-1
concentration [84, 91]. Long lasting, lipid-lowering
therapy is associated with a reduction in sCD40
plasma level [88]. The pleiotropic effect of statins
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provides a novel insight into their anti-inflammato-
ry properties, which can be especially important for
patients with high sCD40L concentrations [120].
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